<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03090048</url>
  </required_header>
  <id_info>
    <org_study_id>Tawar -1</org_study_id>
    <nct_id>NCT03090048</nct_id>
  </id_info>
  <brief_title>Vitamin A and Azithromycin for Acne Vulgaris</brief_title>
  <official_title>Treatment of Acne for Cases Resistant to Currently Available Measures Via Vitamin A With or Without Azithromycin in Topical Formulations</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Manchanda Medical Clinic</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Manchanda Medical Clinic</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients seen with acne lesions not having responded to existing treatments will be offered a
      placebo or a topical preparation consisting of Vitamin A USP with or without Azithromycin for
      a duration of 4-6 months USP for the objective of resolving the lesions without systemic side
      effects and via weekly follow-ups.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The concentrations of the active ingredients is based on the enclosed articles and the
      formulations have been modified with an objective of minimizing the side effects.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 30, 2018</start_date>
  <completion_date type="Anticipated">December 20, 2018</completion_date>
  <primary_completion_date type="Anticipated">September 20, 2018</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Measurement (dimensions) of acne lesions</measure>
    <time_frame>Every 4 weeks up to16 weeks</time_frame>
    <description>follow-up focussed on observation of changes</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Vitamin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>retinyl palmitate USP</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin with Vitamin A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>USP grade ingredients</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Azithromycin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>azithromycin monohydrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vitamin A</intervention_name>
    <description>Vitamin A 2-3 % concentration</description>
    <arm_group_label>Vitamin A</arm_group_label>
    <arm_group_label>Azithromycin with Vitamin A</arm_group_label>
    <other_name>retinyl palmitate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Azithromycin</intervention_name>
    <description>azithromycin monohydrate</description>
    <arm_group_label>Azithromycin with Vitamin A</arm_group_label>
    <arm_group_label>Azithromycin</arm_group_label>
    <other_name>azithromycin monohydrate</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with active lesions

        Exclusion Criteria:

          -  Patients on a treatment

          -  Asymptomatic patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vinod C Tawar</last_name>
    <role>Study Director</role>
    <affiliation>M.D.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vinod C Tawar, M.Sc., M.D.</last_name>
    <phone>604 754 2235</phone>
    <email>Tawar.vinod@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Manchanda Mc</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3W2T2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>VINOD TAWAR, MD</last_name>
      <phone>604 754 2235</phone>
      <email>TAWAR.VINOD@YAHOO.COM</email>
    </contact>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <results_reference>
    <citation>Bartlett KB, Davis SA, Feldman SR. Tolerability of topical antimicrobials in treatment of acne vulgaris. J Drugs Dermatol. 2014 Jun;13(6):658-62. Review.</citation>
    <PMID>24918554</PMID>
  </results_reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 29, 2017</study_first_submitted>
  <study_first_submitted_qc>March 21, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 24, 2017</study_first_posted>
  <last_update_submitted>May 23, 2018</last_update_submitted>
  <last_update_submitted_qc>May 23, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Manchanda Medical Clinic</investigator_affiliation>
    <investigator_full_name>DR. VINOD C TAWAR</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamins</mesh_term>
    <mesh_term>Vitamin A</mesh_term>
    <mesh_term>Retinol palmitate</mesh_term>
    <mesh_term>Azithromycin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

